Altimmune (ALT) Cash from Financing Activities (2010 - 2026)

Altimmune (ALT) has 17 years of Cash from Financing Activities data on file, last reported at $78.5 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 130.0% year-over-year to $78.5 million in Q1 2026; TTM through Mar 2026 was $251.2 million, a 465.45% increase from a year earlier, with the FY2025 full-year figure at $206.8 million, up 1959.36% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $78.5 million, down from $81.1 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for ALT reached as high as $81.1 million in Q4 2025 and fell as low as -$302000.0 in Q1 2023.
• Historically, Cash from Financing Activities has averaged $25.8 million across 5 years, with a median of $13.1 million in 2023.
• On a YoY basis, Cash from Financing Activities climbed as much as 169295.35% in 2023 and fell as far as 109.49% in 2023.
• Year by year, Cash from Financing Activities stood at -$43000.0 in 2022, then surged by 169295.35% to $72.8 million in 2023, then sank by 86.14% to $10.1 million in 2024, then jumped by 704.46% to $81.1 million in 2025, then retreated by 3.27% to $78.5 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $78.5 million in Q1 2026, $81.1 million in Q4 2025, and $39.3 million in Q3 2025.